In those confirmed with lung cancer by the diagnostic imaging and protein tumor markers but failure with the biopsy procedure, or inadequate tumor tissue for EGFR mutation analysis, clinical doctors should require the mutation testing in plasma before starting chemo-radiotherapy. This evidence concerns the gene EGFR and neoplasm.